Maxcyte (MXCT) Gross Profit (2020 - 2026)

Maxcyte (MXCT) has 7 years of Gross Profit data on file, last reported at $8.1 million in Q1 2026.

• On a quarterly basis, Gross Profit fell 9.12% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $26.0 million, a 14.73% decrease from a year earlier, with the FY2025 full-year figure at $26.8 million, down 14.98% from the prior year.
• Gross Profit for Q1 2026 stood at $8.1 million, up from $5.7 million in the prior quarter.
• Over the last five years, Gross Profit for MXCT reached as high as $14.1 million in Q4 2023 and fell as low as $5.2 million in Q3 2025.
• Historically, Gross Profit has averaged $8.4 million across 5 years, with a median of $8.1 million in 2026.
• Across the five-year window, Gross Profit soared 81.4% in 2022 and tumbled 54.5% in 2024, its largest moves.
• Year by year, Gross Profit stood at $10.9 million in 2022, then advanced by 29.56% to $14.1 million in 2023, then slumped by 54.5% to $6.4 million in 2024, then dropped by 11.26% to $5.7 million in 2025, then surged by 42.04% to $8.1 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $8.1 million in Q1 2026, $5.7 million in Q4 2025, and $5.2 million in Q3 2025.